Unjha Formulations Limited (BOM:531762)
27.49
-0.01 (-0.04%)
At close: Aug 18, 2026
Unjha Formulations Revenue
Unjha Formulations had revenue of 33.07M INR in the quarter ending June 30, 2026, a decrease of -9.01%. This brings the company's revenue in the last twelve months to 152.58M, up 12.11% year-over-year. In the fiscal year ending March 31, 2026, Unjha Formulations had annual revenue of 155.85M with 11.89% growth.
Revenue (ttm)
152.58M
Revenue Growth
+12.11%
P/S Ratio
0.81
Revenue / Employee
10.19M
Employees
15
Market Cap
123.21M
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Mar 31, 2026 | 155.85M | 16.56M | 11.89% |
| Mar 31, 2025 | 139.30M | -45.66M | -24.69% |
| Mar 31, 2024 | 184.96M | 53.42M | 40.61% |
| Mar 31, 2023 | 131.54M | -10.24M | -7.22% |
| Mar 31, 2022 | 141.77M | 42.16M | 42.32% |
| Mar 31, 2021 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Mar 31, 2020 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Mar 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Mar 31, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Mar 31, 2017 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Related Stocks
| Company Name | Revenue |
|---|---|
| Add-Shop E-Retail | 1.71B |
| Vivanza Biosciences | 1.17B |
| Beryl Drugs | 215.51M |
| Zenith Healthcare | 107.48M |
| Hamps Bio | 84.75M |
| Norris Medicines | 75.77M |
| Desh Rakshak Aushdhalaya | 66.33M |
| Colinz Laboratories | 58.11M |